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ABSTRACT
One hundred six HIV-infected patients with chronic hepatitis C virus (HCV) infection were randomized to
receive ribavirin (RBV) 400 mg bid plus interferon a-2b (IFN-a) at two different doses, 3 mU tiw (control
arm) or 5 mU daily for the first 6 weeks, followed by 3 mU tiw until completing 6 months of therapy (induc-
tion arm). All patients had CD4 counts above 350 cells/ml and 89% were taking antiretroviral therapy. Ad-
verse effects leading to treatment discontinuation occurred in 12.3% of patients, a rate quite similar to that
seen in HCV-monoinfected patients. Negative serum HCV-RNA values (,60 IU/ml) were recorded in 24.7%
and 35.5% of patients at 3 and 6 months of therapy. However, in the intent-to-treat analysis, sustained re-
sponse was reached by only 16% of patients (22.4% in the on-treatment analysis). No differences between
treatment arms were noticed. Patients with HCV genotypes 2 or 3 had a 7-fold higher response rate than
those with HCV genotypes 1 or 4. Therefore, early, end-of-treatment, and sustained response rates are lower
in HIV/HCV-coinfected patients treated with RBV/IFN-a combination therapy. Since HCV-related liver dis-
ease is currently one of the leading causes of morbidity and mortality among HIV-infected patients, new treat-
ment options are urgently needed for coinfected individuals.
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INTRODUCTION
HEPATITIS C VIRUS (HCV) infection is quite common amongHIV-infected persons. For individuals who acquired HIV
through parenteral routes (i.e., intravenous drug users or he-
mophiliacs), the rate of chronic HCV infection is above 75%.1,2
Given that the life expectancy of HIV-positive persons has im-
proved dramatically since the introduction of highly active an-
tiretroviral therapy, end-stage liver disease due to HCV is now
a relevant and growing problem among HCV/HIV-coinfected
patients. In fact, liver failure is currently the leading cause of
death among HIV-infected persons in places where a large num-
ber of patients are former drug addicts.3–5
Combination therapy with interferon-a (IFN-a) plus rib-
avirin (RBV) was the standard of care for treating HCV infec-
tion in HIV-negative individuals until recent times.6,7 More re-
cently, a pegylated formulation of IFN-a has been used with
higher success than the classic IFN-a,8,9 and together with RBV
is now the preferred treatment choice for chronic hepatitis C.10
A successful response to anti-HCV therapy requires the defin-
itive elimination of the virus from the infected host, which may
be presumed when serum HCV-RNA becomes undetectable 6
months after ending treatment. Overall, this sustained response
(SR) is achieved using combination therapy in nearly 40% of
patients treated with IFN-a plus RBV,11,12 and up to nearly
50% when pegylated IFN-a plus RBV is used.8,9 In any case,
patients with HCV genotypes 2 or 3 show a higher response
(,3-fold) than those with HCV genotypes 1 or 4.8–12 Prelimi-
nary results suggest that using greater doses of IFN-a or a more
frequent administration of the drug might increase the response
rate, particularly in subjects carrying HCV genotype 1,13,14 al-
though side effects may then become a major issue.
Information on the efficacy and safety of combination ther-
apy with IFN-a plus RBV in HCV/HIV-coinfected patients is
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limited to a few studies in which a small number of patients
had been recruited, and often with unfavorable profiles, such
as previous IFN-a experience, advanced stages of liver fibro-
sis, and/or low CD4 counts.15–18 Herein, we report the final re-
sults of a multicenter trial in which two different doses of IFN-a
plus RBV were prescribed to a large group of not severely im-
munosuppressed HIV-positive individuals with chronic hepati-
tis C, all naive for IFN-a.
PATIENTS AND METHODS
Patients
The study begun in January 2000, and the recruitment pe-
riod extended for 1 year. It was designed as an open, prospec-
tive, multicenter, randomized, comparative trial. It was ap-
proved by the Ethical Committee of each of the participating
institutions. Inclusion criteria required age between 18 and 55
years, elevated transaminase levels (either ALT or AST) above
1.5 the upper normal limit during the preceding 6 months, re-
activity to HCV antibodies, and the presence of serum HCV-
RNA. Although a liver biopsy was recommended before be-
ginning therapy, it was not mandatory for recruitment in the
trial. All patients were naive for IFN-a.
Among the exclusion criteria were positivity for HBsAg, his-
tory of decompensated cirrhosis, platelet counts below 75,000
cells/ml, hemoglobin levels below 11 g/dl, previous history of
severe psychiatric illness, autoimmune disease, current signif-
icant alcohol intake (.50 g daily), or any recent engagement
in drug addiction practices. Moreover, only patients having HIV
infection under control were recruited in the trial. Accordingly,
only those with CD41 counts above 350 cells/ml and plasma
HIV-RNA below 5000 copies/ml, with or without antiretrovi-
ral therapy, were eligible. All patients gave informed consent
before being included in the trial.
Study medication
Interferon-a-2b (Intron A, Schering-Plough, Kenilworth, NJ)
and ribavirin (Rebetol, Schering-Plough, Kenilworth, NJ) were
the study drugs. Two doses of IFN-a were examined. In the
control arm, standard doses of 3 megaunits three times per week
were prescribed, whereas 5 megaunits of IFN-a were given
daily for the first 6 weeks in subjects allocated into the induc-
tion arm. All patients were allowed to complete 6 months of
therapy with standard doses of IFN-a (3 megaunits tiw) plus
RBV. The dose of RBV was of 400 mg bid in both treatment
arms, irrespective of the weight of patients.
Laboratory tests
Baseline HCV-RNA was measured using a commercially
available reverse transcriptase polymerase chain reaction
(RT/PCR) assay (Cobas Amplicor HCV Monitor v2.0; Roche,
Barcelona, Spain), which has a detection limit of 600 IU/ml.
HCV genotype was determined with a commercial strip hy-
bridization test (LiPA HCV II; Bayer, Barcelona, Spain). The
presence of serum HCV-RNA in subjects undergoing therapy
and thereafter was examined using a qualitative assay (Cobas
Amplicor HCV; Roche, Barcelona, Spain), which has a detec-
tion limit of 60 IU/ml.
Plasma HIV-RNA was measured using the bDNA assay
(Quantiplex v3.0, Bayer, Barcelona, Spain), which has a de-
tection limit of 50 copies/ml. Absolute numbers of CD41 T
cells in peripheral blood were determined by flow cytometry
(Coulter, Madrid, Spain).
Patient’s monitoring
All subjects recruited in the study were seen every 4 weeks
after beginning treatment. Hemoglobin, platelets, leukocytes,
transaminases, amylase, lactate, CD4 lymphocyte counts, and
plasma HIV-RNA were recorded at each time point. After end-
ing 6 months on therapy, visits were programmed every 3
months.
Statistical analyses
Results are expressed in absolute values and percentage.
Continuous variables are expressed as mean values 6 standard
deviation. Means were compared using the Mann–Whitney rank
sum test. Categorical variables were compared using the
Fisher’s exact or the chi-square tests. Response rates were es-
timated on an intent-to-treat basis (missing 5 failure) as well
as considering only subjects on treatment. Univariate and mul-
tivariate logistic regression analyses were performed for ex-
amining the potential predictors of response to therapy. All p
values were two-tailed, and differences were considered sig-
nificant when p was below 0.05. All data analyses were con-
ducted using the SPSS for Windows, version 10.0 (SPSS Inc,
Chicago, IL).
RESULTS
A total of 106 subjects (79% male; mean age 37 years old)
were recruited in 13 centers participating in the trial. A total of
89% of patients were under antiretroviral therapy. All treated
subjects received triple or quadruple drug combinations, using
generally two nucleoside analogs along with protease inhibitors
(37%) or nonnucleosides (62%). Of note, 71% of patients were
taking stavudine (d4T), 28% were on dideoxyinosine (ddl), and
25% on zidovudine (AZT).
HCV genotype distribution was 1 (55%), 3 (34%), and 4
(11%). Mean plasma HCV-RNA at baseline was 2,011,565
IU/ml, and 54% of patients harbored .800,000 IU/ml. The
main characteristics of the study population at baseline in the
two treatment arms are recorded in Table 1. No significant dif-
ferences were noted when comparing them.
Data on liver histology were available for only 24 subjects,
given that biopsy was not mandatory in this trial. It should be
noted that in all instances significant liver fibrosis (stages F2
to F4 using the Metavir score) were recognized, with different
degrees of necroinflammation. Ten patients showed liver cir-
rhosis (F4).
Side effects of any grade were recorded in 93 of patients
(92%). In order of frequency, the most frequent were malaise
(69%), fever (61%), mialgias (51%), depression (38%), nausea-
vomiting (31%), anemia (28%), weight loss (26%), local in-
flammation at the site of injection (18%), insomnia (14%),
thrombopenia (9%), abdominal pain (6%), and psychotic reac-
tion (3%).
A total of 30 subjects did not complete the study. Seventeen
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(16%) were lost to follow-up; in some cases coincident with
new engagement in drug addiction practices, changes of city to
live, request to be in jail, etc. Treatment discontinuation due to
adverse effects considered to be related to the study medication
occurred in 13 (12.3%) patients, seven from the induction arm
and six from the control arm. The reasons are recorded in Table
2. Another three subjects showed grade 2–3 increases in serum
amylases without clinical symptoms or just mild abdominal dis-
comfort, which normalized after discontinuing anti-HCV ther-
apy at the end of treatment. All three were taking ddI con-
comitantly. Another two subjects showed mild increases in
lactate levels without clinical symptoms of lactic acidosis. Both
were taking d4T. Hyperamylasemia and hyperlactatemia re-
solved in all these subjects after completing anti-HCV therapy
and discontinuing IFN-a plus RBV. Of note, no patients with-
drew therapy due to anemia, although two needed reductions
in the RBV dose. Neither significant drops in the CD4 count
nor increases in plasma HIV-RNA were seen, even in subjects
in whom RBV was taking concomitantly with AZT or d4T. Of
note, body weight declined a mean of 4.3 kg from baseline
(mean of 69.2 kg) among subjects who completed 6 months on
therapy.
Serum HCV-RNA clearance at month 3 (early response) was
seen in 20 (24.7%) of 81 patients on treatment, whereas it was
recorded in 27 (35.5%) of 76 patients who completed 6 months
of therapy (end-of-treatment response, ETR). Relapses occurred
in 10 (37%) of them within the following 6 months. Thus, the
overall SR rate in this trial was 22.4% (17/75). In the intent-to-
treat analyses these figures were 18.9% for early response,
25.5% for ETR, and 16% (17/106) for SR. No significant dif-
ferences between treatment arms were noticed. Of note, 70%
of responders carried HCV-3. Table 3 summarizes the response
rates according to HCV genotypes in each treatment arm at dif-
ferent time points.
Table 4 shows the predictive value of reaching SR for sev-
eral variables, including age, HCV genotype, serum HCV-
RNA, treatment arm, concomitant antiretroviral therapy, CD4
counts, and RBV dose. Only infection with HCV genotype 3
was significantly associated with a greater likelihood of reach-
ing SR, both in univariate and multivariate analyses. Patients
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TABLE 1. BASELINE CHARACTERISTICS OF THE STUDY POPULATION
Induction arm Control arm Total
No. 49 (46%) 57 (54%) 106
Gender (male) 40 (82%) 44 (77%) 84 (79%)
Mean age (years) 36.6 6 5.5 37.2 6 5 36.9 6 5.2
HIV transmission route 41 (84%) 46 (81%) 87 (82%)
(intravenous drug use)
Mean weight (kg) 69.6 6 9.1 68.1 6 82 69.1 6 10.2
HCV genotypes
1 or 4 32 (65%) 38 (67%) 70 (66%)
2 or 3 17 (35%) 19 (33%) 36 (34%)
Serum HCV-RNA (IU/ml)
Mean 1,772,482 2,208,704 2,011,565
No. with .800,000 24 (51%) 32 (56%) 56 (53%)
Mean ALT levels (IU/ml) 126.6 6 23.2 118.2 6 26.4 122.5 6 27.1
Mean CD4 count (cells/ml) 525 6 108 496 6 124 512 6 132
No. of patients on 40 (82%) 54 (95%) 94 (89%)
antiretroviral therapy
TABLE 2. SIDE EFFECTS LEADING TO TREATMENT DISCONTINUATION
Patient Time on treatment
no. Main adverse events Treatment arm (months)
1 Malaise, fever Induction 1
2 Transaminase elevation Induction 1
3 Depression Control 3
4 Nausea, vomiting, abdominal pain Control 3
5 Fever, malaise Control 1
6 Psychotic reaction Control 1
7 Psychotic reaction Control 1
8 Malaise, mialgias, depression Induction 3
9 Thrombopenia Control 1
10 Depression Induction 1
11 Weight loss Induction 3
12 Malaise, jaundice Induction 3
13 Psychotic reaction Control 3
 
with HCV genotype 3 had a 7-fold higher chance of response
than those with HCV genotypes 1 or 4 (OR, 9.7; 95% confi-
dence interval, 2.7 to 35.2; p 5 0.0001).
Although many subjects who reached SR had cleared HCV-
RNA 4 weeks after beginning therapy, seven (41.2%) of them
showed a delayed virological response, in three (17.6%) of them
even beyond 12 weeks of therapy, and this was independent of
the HCV genotype.
DISCUSSION
This trial shows that combination therapy with IFN-a plus
RBV is relatively safe in HIV-coinfected individuals with
chronic hepatitis C. Overall, treatment was discontinued due to
adverse events in 12% of patients, a rate similar to that seen in
HCV-monoinfected individuals.8–12 Moreover, unexpected side
effects were not recorded, although three patients developed
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TABLE 3. NEGATIVE SERUM HCV-RNA ACCORDING TO HCV GENOTYPES AT DIFFERENT
TIME-POINTS USING INTENT-TO-TREAT (ITT) AND ON-TREATMENT (OT) ANALYSES
Early response End-of-treatment response Sustained response
(3 months) (6 months) (12 months)
Genotypes Genotypes Genotypes Genotypes Genotypes Genotypes
1 and 4 2 and 3 Total 1 and 4 2 and 3 Total 1 and 4 2 and 3 Total
Induction arm
ITT 1/32 10/17 11/49 2/32 11/17 13/49 1/32 9/17 10/49
(22.4%) (26.5%) (20.4%)
OT 1/21 10/14 11/35 2/20 11/13 13/33 1/20 9/13 10/33
(31.4%) (39.4%) (30.3%)
Control arm
ITT 3/38 6/19 9/57 6/38 8/19 14/57 3/38 4/19 7/57
(15.8%) (24.6%) (12.3%)
OT 3/31 6/15 9/46 6/29 8/14 14/43 3/29 4/14 7/43
(19.6%) (32.6%) (16.3%)
TABLE 4. VARIABLES ASSOCIATED WITH THE ACHIEVEMENT OF SUSTAINED RESPONSE
Rate of sustained
No. response p
Age (years)
, 40 82 13 (16%) n.s.a
. 40 24 4 (17%)
CD4 count (cells/ml)
. 500 79 13 (17%) n.s.
, 500 27 4 (16%)
Baseline serum HCV-RNA (IU/ml)
, 800,000 49 11 (22%) n.s.
. 800,000 57 6 (11%)
HCV genotype
2 and 3 36 13 (36%) 0.0001
1 and 4 70 4 (6%)
Ribavirin dose
. 10.6 mg/kg 77 12 (15.6%) n.s.
, 10.6 mg/kg 29 5 (17.2%)
Treatment modality
Induction arm 49 10 (20%) n.s.
Control arm 57 7 (12%)
Estimated duration of HCV
infection (years)
, 5 21 2 (10%) n.s.
. 5 85 15 (18%)
Antiretroviral therapy
No 12 3 (25%) n.s.
Yes 94 14 (15%)
an.s., not significant.
 
asymptomatic hyperamylasemia, which disappeared after dis-
continuing therapy. All of them were taking ddl concomitantly.
Moreover, lactate levels increased slightly in two individuals,
both of whom were taking d4T. Recently, reports of fatal de-
velopment of lactic acidosis and/or pancreatitis have appeared
in HIV/HCV-coinfected patients receiving concomitantly RBV
with either d4T and/or ddI, particularly in the setting of cirrho-
sis.19–22 Although liver histology was not available in many of
our patients, fibrosis in different extent was uniformly demon-
strated, with liver cirrhosis in up to 40% of biopsied cases, in
agreement with other reports that have proven advanced liver fi-
brosis in a high proportion of HIV/HCV-coinfected pa-
tients.23–25 This circumstance should have favored the recogni-
tion of any of these complications in our series. Therefore, our
data do not support the removal of d4T and/or ddI when treat-
ment with RBV is planned, although close monitoring of symp-
toms, and amylase, lipase, and lactate levels may be warranted.
One interesting finding in our study was the recognition of
a significant weight loss (4.3 kg on average within 6 months),
which exceeded what is generally seen in HIV-negative indi-
viduals undergoing anti-HCV combination therapy. Long-term
exposure to nucleoside analogs, and particularly d4T, has been
associated with lipoatrophy in HIV-infected patients, most
likely throughout a mechanism of mitochondrial damage.26,27
We wonder whether a potentiation of this side effect of nucle-
oside analogs with RBV could account for our findings. In fact,
more than two-thirds of the patients recruited in our trial were
taking d4T. As occurs with the greater risk of pancreatitis when
taking ddI and RBV, a significant weight loss might be another
characteristic side effect resulting from the interaction of RBV
with nucleoside analogs.
The SR rate of 22% recorded in this study (16% in the in-
tent-to-treat analysis) is much lower than that seen in HIV-neg-
ative individuals with chronic hepatitis C treated with IFN-a
and RBV.11,12 Several reasons may account for this fact. Some
of them are related to the trial design, such as the decision to
use low doses of RBV in subjects weighing more than 75 kg
or to prescribe treatment for only 6 months in subjects with
HCV genotypes 1 or 4. The use of doses of RBV adjusted to
body weight (.10.6 mg/kg) has recently been shown to result
in greater response rates.8 We chose the 400 mg bid fixed dose
of RBV because of concern for potential deleterious interac-
tions when concomitantly taking some antiretroviral drugs (i.e.,
anemia with AZT, or pancreatitis with ddI).17–22 It should be
noted, however, that less than one-third of our study popula-
tion received less than 10.6 mg/kg of RBV, and that no signif-
icant differences were noticed when comparing the response
rate achieved in those with or without RBV exposure above
10.6 mg/kg.
A different consideration could apply to the short length of
treatment in our trial for patients with HCV genotypes 1 or 4.
The prescription of anti-HCV therapy for only 6 months was
mainly based on the concern for a greater risk of toxicity and
of poor adherence when concomitantly taking IFN-a plus RBV
along with triple antiretroviral drug combinations for long pe-
riods of time. Different studies have demonstrated that patients
with HCV genotypes 1 or 4 experience a greater benefit when
treatment is extended to 1 year.6,28 In our trial, only 5% of sub-
jects with HCV genotypes 1 or 4 reached SR. Although this
rate is clearly below expectations, it should be noted that the
response in subjects with HCV genotype 3 occurred in only
36%, which is half the response obtained in HIV-negative pa-
tients.6,11,12 Therefore, although the treatment schedule might
have contributed to explaining the overall lower response rate
seen in our trial, other factors most likely account for it.
Specific characteristics of HCV infection in the setting of
HIV, such as higher HCV load or greater HCV quasispecies di-
versity, both of which are considered to be predictors of poor
response to anti-HCV therapy,28,29 could have contributed to the
low response rate seen in our trial. Moreover, HIV-infected in-
dividuals may show a lower immune response against HCV, and
might support a weaker immune-mediated clearance activity to
IFN-a and/or IFN-a plus RBV. Finally, the interaction between
thymidine analogs (AZT and d4T) and RBV is not well known
in vivo. Preliminary studies have reported no evidence of a re-
duced anti-HIV activity of AZT or d4T when RBV is coad-
ministered.30,31 However, no data exist on a possible reduced
anti-HCV activity of RBV in the presence of AZT or d4T.
The recognition of early predictors of lack of an SR in pa-
tients receiving IFN-a plus RBV may allow us to stop earlier
a medication that is poorly tolerated and would not benefit the
patient. In HIV-negative individuals, the presence of serum
HCV-RNA is detectable at different time points whereas being
on treatment is a good predictor of lack of SR.6 Using IFN-a
monotherapy, treatment discontinuation was recommended at
3 months in the presence of detectable serum HCV-RNA6; how-
ever, this decision-making time point was extended to 6 months
using IFN-a plus RBV, since about 10% of subjects showed a
delayed HCV-RNA clearance.12 No data are available so far on
the best time to discontinue therapy in HIV/HCV-coinfected
subjects receiving IFN-a plus RBV. This information is ex-
tremely important in this population, since anti-HCV treatment
is frequently associated with side effects,32 is expensive, re-
duces dramatically the patient’s quality of life, and, as stated
before, there is growing concern on the risks of interactions be-
tween RBV and antiretroviral drugs.17–22 In our trial, we specif-
ically examined whether the recognition of negative serum
HCV-RNA at different time points could be used for early ther-
apy-off decision making. Negative serum HCV-RNA among
subjects who later achieved SR was recognized in 62% of cases
at month 1 and in 82.4% at month 3. However, 3 of 17 subjects
who reached SR cleared HCV-RNA after the third month of
therapy. Of note, responders carrying HCV genotype 3 did not
have an apparently faster HCV-RNA clearance than those with
HCV genotypes 1 or 4. In agreement with our findings, a recent
report has pointed out that HCV/HIV-coinfected patients may
show a delayed clearance of serum HCV-RNA under IFN-a.33
Therefore, our results suggest that monitoring the response to
IFN-a plus RBV in HIV/HCV-coinfected patients with a sen-
sitive HCV-RNA qualitative test does not permit us to discon-
tinue treatment earlier presuming that SR will not occur. Fur-
ther studies are needed to determine whether monitoring the
response to anti-HCV treatment with an HCV-RNA quantita-
tive assay, following what is standard practice in HIV infec-
tion,34 may allow us to recognize much earlier (just 1 or 3
months after beginning IFN-a plus RBV) a minimal drop (i.e.,
of 2 logs), below which no treatment response should be ex-
pected, and therefore treatment discontinuation might be war-
ranted. This has been recently proven to be useful in HCV-
monoinfected patients using pegylated IFN-a and RBV.9 As we
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enter an era in which HCV treatment is going to be aggres-
sively pursued in HIV/HCV-coinfected persons, being able to
recognize at early time points who will not benefit from an ex-
pensive and poor tolerated therapy must warrant more atten-
tion.
In summary, our results show that the combination of IFN-a
plus RBV is relatively well tolerated in HIV/HCV-coinfected
patients. The rate of treatment discontinuation found in this
study (12%) is similar to that seen in HIV-negative individu-
als, without the appearance of unexpected side effects. How-
ever, the SR rate was 22.4%, which is lower than that seen in
HIV-negative counterparts. Although the short duration of ther-
apy (6 months) for patients carrying HCV-1 and/or the low dose
of RBV (800 mg bid) for patients with high weight could have
contributed to explaining this limited benefit, other reasons are
most likely involved, since early and end-of-treatment re-
sponses were equally much lower than those seen in HCV-
monoinfected patients. This information should be useful for
clinicians, who will need to balance on an individual basis who
should be treated for chronic hepatitis C. On one hand, the re-
sponse rate to anti-HCV therapy seems to be lower in HIV-
coinfected patients, and side effects may be frequent, including
those resulting from the interaction with antiretroviral drugs.
On the other hand, the benefit of curing HCV infection may
impact positively on several aspects of HIV disease, including
a much better tolerance of antiretroviral drugs,35 an ameliora-
tion or complete stop in the progression of liver disease to cir-
rhosis or even hepatocellular carcinoma,36 and a suppression of
the deleterious effect that HCV seems to play on HIV disease
progression.37,38
APPENDIX: MEMBERS OF THE HCV/HIV
SPANISH STUDY GROUP
Anna Ochoa and Javier Martínez-Lacasa, Mútua de Terrassa,
Terrassa.
Mercé Roget, Hospital de Terrassa, Terrassa.
Juan González and José Ramón Arribas, Hospital La Paz,
Madrid.
Dolores Morales and Miguel Colmenero, Hospital Virgen
Macarena. Seville.
Francisco García de la Llana, Hospital Infanta Cristina,
Badajoz.
Pilar Barrera, Hospital Reina Sofia, Córdoba.
Vicente Torrente and Carlos Alonso-Villaverde, Hospital de
Sant Joan, Reus.
Miguel Santín, Hospital de Bellvitge, L’Hospitalet de Llo-
bregat.
Josep Guardiola and Josep Cadafalch, Hospital de Sant Pau,
Barcelona.
Fausto Sánchez-Montero, Complejo Hospitalario. Cáceres.
Jesús Blanch, Javier García-Pont, and Lluis Moner, Hospi-
tal de Sant Camil, Barcelona.
Victor Asensi, Hospital Central de Asturias, Oviedo.
Mayte Pérez-Olmeda, Miriam Romero, Marina Núñez, Pablo
Barreiro, Inmaculada.
Jiménez-Nácher, Javier García-Samaniego, and Vincent So-
riano, Instituto de Salud Carlos III, Madrid.
ACKNOWLEDGMENTS
This work was supported in part by grants from AIES,
RIS(project 173), RTIC G03/015, and CAM. We would like to
thank Prof. Gonzalez-Lahoz for his continuous support.
REFERENCES
1. Bonacini M and Puoti M: Hepatitis C in patients with HIV infec-
tion. Arch Intern Med 2000;160:3365–3373.
2. Sherman K, Rouster S, Chung R, and Rajicic N: Hepatitis C virus
prevalence among patients infected with HIV: A cross-sectional
analysis of the US ACTG. Clin Infect Dis 2002;34:831–837.
3. Puoti M, Spinetti A, Ghezzi A, et al.: Mortality for liver disease
in patients with HIV infection: A cohort study. J Acquir Immune
Defic Syndr 2000;24:211–217.
4. Martín-Carbonero L, Soriano V, Valencia ME, García-Samaniego
J, López M, and González-Lahoz J: Impact of chronic viral he-
patitis on hospital admission and mortality in HIV-infected patients.
AIDS Res Hum Retroviruses 2001;17:1467–1471.
5. Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to
end-stage liver disease in patients with HIV infection. Clin Infect
Dis 2001;32:492–497.
6. EASL Panel: EASL Consensus Statement on hepatitis C. J Hepa-
tol 1999;30:956–961.
7. Lauer G and Walker B: Hepatitis C virus infection. N Engl J Med
2001;345:41–52.
8. Manns M, McHutchison J, Gordon S, et al.: Peginterferon alfa-2b
plus ribavirin compared with interferon alfa-2b plus ribavirin for
initial treatment of chronic hepatitis C: A randomized trial. Lancet
2001;358:958–965.
9. Fried M, Shiffman M, Reddy R, et al.: Peginterferon alfa-2a plus
ribavirin for chronic hepatitis C virus infection. N Engl J Med
2002;347:975–982.
10. NIH Consensus Development Conference Statement: Management
of hepatitis C. Gastroenterology 2002;123:2082–2099.
11. McHutchison J, Gordon S, Schiff E, et al.: Interferon alfa-2b alone
or in combination with ribavirin as initial treatment for chronic he-
patitis C. N Engl J Med 1998;339:1485–1492.
12. Poynard T, Marcellin P, Lee S, et al.: Randomized trial of inter-
feron alpha 2b plus ribaviron for 48 weeks or for 24 weeks versus
interferon alpha 2b plus placebo for 48 weeks for treatment of
chronic infection with hepatitis C virus. Lancet 1998;352:1426–
1432.
13. Bruno R, Sacchi P, Maffezzini E, et al.: Daily interferon regimen
for chronic hepatitis C: A prospective randomized study. Clin Drug
Invest 1999;18:11–16.
14. Ferenci P, Brunner H, Nachbaur K, et al.: Combination of inter-
feron induction therapy and ribavirin in chronic hepatitis C. He-
patology 2001;34:1006–1011.
15. Landau A, Batisse D, Piketty C, et al.: Long-term efficacy of com-
bination therapy with interferon a-2b and ribavirin for severe
chronic hepatitis C in HIV-infected patients. AIDS 2001;15:2149–
2156.
16. Nasti G, Di Gennaro G, Tavio M, et al.: Chronic hepatitis C in
HIV infection: Feasibility and sustained efficacy of therapy with
interferon alfa-2b and ribavirin. AIDS 2001;15:1783–1788.
17. Sauleda S, Juárez A, Esteban JI, et al.: Interferon and ribavirin
combination therapy for chronic hepatitis C in HIV-infected pa-
tients with congenital coagulation disorders. Hepatology 2001;34:
1035–1040.
18. Rockstroh J, Mudar M, Lichterfeld M, et al.: Pilot study of inter-
feron alpha high-dose induction therapy in combination with rib-
PÉREZ-OLMEDA ET AL.1088
avirin for chronic hepatitis C in HIV-coinfected patients. AIDS
2002;16:2083–2085.
19. Lafeuillade A, Hittinger G, and Chapadaud S: Increased mito-
chondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet
2001;357:280–281.
20. Kakuda T and Brinkman K: Mitochondrial toxic effects of rib-
avirin. Lancet 2001;357:1802–1803.
21. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B,
and Sogni P: Mitochondrial toxic effects of ribavirin. Lancet 2001;
357:1803–1804.
22. Mauss S, Larrey D, Valenti W, et al.: Risk factors for hepatic de-
compensation in cirrhotic patients with HIV-HCV coinfection
treated with PEG interferon or interferon and ribavirin or placebo.
Sixth International Congress on Drug Therapy in HIV Infection,
Glasgow, November 17–21, 2002 [abstract PL12.4].
23. García-Samaniego J, Soriano V, Castilla J, et al.: Influence of HCV
genotypes and HIV infection on histological severity of chronic he-
patitis C. Am J Gastroenterol 1997;92:1130–1134.
24. Benhamou Y, Bochet M, Di Martino V, et al.: Liver fibrosis pro-
gression in HIV and HCV coinfected patients. Hepatology 1999;30:
1054–1058.
25. Soriano V, Martín-Carbonero L, and García-Samaniego J: Treat-
ment of chronic hepatitis C virus infection: We must target the
virus or liver fibrosis? AIDS 2003;17:751–753.
26. Moyle G: Hyperlactatemia and lactic acidosis during antiretroviral
therapy: Causes, management and possible etiologies. AIDS Rev
2001;3:150–156.
27. Martínez E, Mocroft A, García-Viejo MA, et al.: Risk of lipodys-
trophy in HIV-infected patients treated with protease inhibitors: A
prospective cohort study. Lancet 2001;357:592–598.
28. Poynard T, McHutchison J, Goodman Z, Ling M, and Albrecht J:
Is an “à la carte” combination interferon alfa 2b plus ribavirin reg-
imen possible for the first line treatment in patients with chronic
hepatitis C? Hepatology 2000;31:211–218.
29. Martinot-Peignoux M, Marcellin P, Poureau M, et al.: Pre-treat-
ment HCV-RNA levels and HCV genotype are the main and in-
dependent prognostic factors of sustained response to alpha inter-
feron therapy in chronic hepatitis C. Hepatology 1995;22:1050–
1056.
30. Morsica G, De Bona A, Uberti C, Sitia G, Finzazzi R, and Laz-
zarin A: Ribavirin therapy for chronic hepatitis C does not modify
HIV viral load in HIV-1 positive patients under antiretroviral treat-
ment. AIDS 2000;14:1656–1658.
31. Landau A, Batisse D, Piketty C, Jian R, and Kazatchkine M. Lack
of interference between ribavirin and nucleoside analogues in
HIV/HCV coinfected individuals undergoing concomitant anti-
retroviral therapy. AIDS 2000;14:1857–1858.
32. Torriani F, Ribeiro R, Gilbert T, et al.: Early HCV viral dynamics
in HIV/HCV-infected patients on HCV treatment. Ninth Confer-
ence on Retroviruses and Opportunistic Infections, Seattle, Febru-
ary 2002 [abstract 121].
33. Gervais A, Boyer N, and Marcellin P: Tolerability of treatments
for viral hepatitis. Drug Safety 2001;24:375–384.
34. DHHS: Updated guidelines for the use of antiretroviral agents in
HIV-infected adults and adolescents, February 4, 2002.
http://www.hivatis.org/guidelines/adult/Feb04/AdultGdl.pdf.
35. Núñez M, Lana R, Mendoza JL, Martín-Carbonero L, and Soriano
V: Risk factors for severe hepatic injury after introduction of highly
active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;
27:426–431.
36. García-Samaniego J, Rodríguez M, Berenguer J, Rodríguez-
Rosado R, Asensi V, and Soriano V. Hepatocellular carcinoma in
HIV-infected patients with chronic hepatitis C. Am J Gastroenterol
2001;96:179–183.
37. Greub G, Ledergerber B, Battegay M, et al.: Clinical progression,
survival, and immune recovery during antiretroviral therapy in pa-
tients with HIV-1 and hepatitis C virus coinfections. Lancet 2000;
356:1800–1805.
38. Soriano V, Martín JC, and González-Lahoz J: HIV-1 progression
in hepatitis C-infected drug users. Lancet 2001;357:1361–1362.
Address reprint requests to:
Vincent Soriano
Service of Infectious Diseases
Instituto de Salud Carlos III
Calle Sinesio Delgado 10
Madrid 28029, Spain
E-mail: vsoriano@dragonet.es
TREATMENT OF CHRONIC HCV IN HIV PATIENTS 1089
